Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4716 in KRAS-Altered Advanced or Metastatic Solid Tumors
NCT07247110Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of MK-4716 in solid tumor and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events at 4 years and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
MK-4716
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07247110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07247110.